Revolution Medicines Stock Performance
| RVMD Stock | USD 40.29 0.39 0.98% |
The company holds a Beta of 0.54, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Revolution Medicines' returns are expected to increase less than the market. However, during the bear market, the loss of holding Revolution Medicines is expected to be smaller as well. At this point, Revolution Medicines has a negative expected return of -0.23%. Please make sure to check Revolution Medicines' potential upside, daily balance of power, as well as the relationship between the Daily Balance Of Power and market facilitation index , to decide if Revolution Medicines performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Revolution Medicines has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in February 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.98 | Five Day Return (3.40) | Year To Date Return (8.43) | Ten Year Return 39.41 | All Time Return 39.41 |
1 | Disposition of 2022 shares by Mark Goldsmith of Revolution Medicines at 45.4566 subject to Rule 16b-3 | 10/25/2024 |
2 | Disposition of 5000 shares by Patel Sushil of Revolution Medicines at 24.84 subject to Rule 16b-3 | 10/31/2024 |
3 | Disposition of 5000 shares by Mark Goldsmith of Revolution Medicines at 55.0268 subject to Rule 16b-3 | 11/01/2024 |
4 | Disposition of 36600 shares by Mark Goldsmith of Revolution Medicines at 0.49 subject to Rule 16b-3 | 11/04/2024 |
5 | Revolution Medicines CEO Mark A. Goldsmith sells 3.88 million in stock | 11/05/2024 |
6 | Victory Capital Management Inc. Sells 104,851 Shares of Revolution Medicines, Inc. - MarketBeat | 11/19/2024 |
7 | Revolution Medicines Announces Pricing of Upsized 750.0 Million Public Offering of Common Stock and Pre-Funded Warrants | 12/04/2024 |
8 | Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and ... | 12/05/2024 |
9 | Verition Fund Management LLC Buys New Stake in Revolution Medicines, Inc. - MarketBeat | 12/11/2024 |
10 | Revolution Medicines SWOT analysis RAS inhibitor stock shows promise amid clinical trials | 12/16/2024 |
11 | Disposition of 50900 shares by Mark Goldsmith of Revolution Medicines at 4.09 subject to Rule 16b-3 | 01/03/2025 |
12 | UBS Group Raises Revolution Medicines Price Target to 71.00 | 01/08/2025 |
13 | Revolution Medicines, Inc. The Biotech Stock with Biggest Upside Potential | 01/17/2025 |
| Begin Period Cash Flow | 163.1 M |
Revolution |
Revolution Medicines Relative Risk vs. Return Landscape
If you would invest 4,775 in Revolution Medicines on October 20, 2024 and sell it today you would lose (746.00) from holding Revolution Medicines or give up 15.62% of portfolio value over 90 days. Revolution Medicines is currently does not generate positive expected returns and assumes 2.8588% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than Revolution, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Revolution Medicines Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Revolution Medicines' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Revolution Medicines, and traders can use it to determine the average amount a Revolution Medicines' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0814
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RVMD |
Estimated Market Risk
| 2.86 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Revolution Medicines is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Revolution Medicines by adding Revolution Medicines to a well-diversified portfolio.
Revolution Medicines Fundamentals Growth
Revolution Stock prices reflect investors' perceptions of the future prospects and financial health of Revolution Medicines, and Revolution Medicines fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Revolution Stock performance.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (845.95) % | ||||
| Current Valuation | 5.98 B | ||||
| Shares Outstanding | 184.8 M | ||||
| Price To Book | 4.71 X | ||||
| Price To Sales | 10,034 X | ||||
| Revenue | 11.58 M | ||||
| Gross Profit | (425.4 M) | ||||
| EBITDA | (430.58 M) | ||||
| Net Income | (436.37 M) | ||||
| Cash And Equivalents | 461.43 M | ||||
| Cash Per Share | 5.26 X | ||||
| Total Debt | 87.94 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 7.60 X | ||||
| Book Value Per Share | 9.34 X | ||||
| Cash Flow From Operations | (350.57 M) | ||||
| Earnings Per Share | (3.66) X | ||||
| Market Capitalization | 7.45 B | ||||
| Total Asset | 2.06 B | ||||
| Retained Earnings | (1.14 B) | ||||
| Working Capital | 1.74 B | ||||
About Revolution Medicines Performance
By analyzing Revolution Medicines' fundamental ratios, stakeholders can gain valuable insights into Revolution Medicines' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Revolution Medicines has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Revolution Medicines has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.23) | (0.24) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.22) | (0.23) |
Things to note about Revolution Medicines performance evaluation
Checking the ongoing alerts about Revolution Medicines for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Revolution Medicines help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Revolution Medicines generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 11.58 M. Net Loss for the year was (436.37 M) with loss before overhead, payroll, taxes, and interest of (425.4 M). | |
| Revolution Medicines currently holds about 461.43 M in cash with (350.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.26. | |
| Revolution Medicines has a poor financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Revolution Medicines, Inc. The Biotech Stock with Biggest Upside Potential |
- Analyzing Revolution Medicines' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Revolution Medicines' stock is overvalued or undervalued compared to its peers.
- Examining Revolution Medicines' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Revolution Medicines' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Revolution Medicines' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Revolution Medicines' stock. These opinions can provide insight into Revolution Medicines' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Revolution Stock analysis
When running Revolution Medicines' price analysis, check to measure Revolution Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines is operating at the current time. Most of Revolution Medicines' value examination focuses on studying past and present price action to predict the probability of Revolution Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines' price. Additionally, you may evaluate how the addition of Revolution Medicines to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |